Jazz Pharmaceuticals Plc (JAZZ)
246.81
-0.76
(-0.30%)
USD |
NASDAQ |
Sep 04, 16:00
246.82
+0.01
(+0.00%)
After-Hours: 20:00
Jazz Pharmaceuticals Research and Development Expense (Quarterly) : 207.50M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 207.50M |
| March 31, 2026 | 196.00M |
| December 31, 2025 | 213.91M |
| September 30, 2025 | 198.20M |
| June 30, 2025 | 189.97M |
| March 31, 2025 | 180.65M |
| December 31, 2024 | 240.50M |
| September 30, 2024 | 199.92M |
| June 30, 2024 | 220.73M |
| March 31, 2024 | 222.85M |
| December 31, 2023 | 216.61M |
| September 30, 2023 | 234.40M |
| June 30, 2023 | 209.24M |
| March 31, 2023 | 189.41M |
| December 31, 2022 | 172.56M |
| September 30, 2022 | 148.87M |
| June 30, 2022 | 139.05M |
| March 31, 2022 | 129.98M |
| December 31, 2021 | 155.44M |
| September 30, 2021 | 141.04M |
| June 30, 2021 | 132.70M |
| March 31, 2021 | 76.57M |
| December 31, 2020 | 91.70M |
| September 30, 2020 | 78.65M |
| June 30, 2020 | 78.92M |
| Date | Value |
|---|---|
| March 31, 2020 | 86.11M |
| December 31, 2019 | 97.38M |
| September 30, 2019 | 79.86M |
| June 30, 2019 | 62.38M |
| March 31, 2019 | 60.10M |
| December 31, 2018 | 56.66M |
| September 30, 2018 | 51.16M |
| June 30, 2018 | 56.13M |
| March 31, 2018 | 62.67M |
| December 31, 2017 | 66.00M |
| September 30, 2017 | 47.36M |
| June 30, 2017 | 40.16M |
| March 31, 2017 | 44.93M |
| December 31, 2016 | 44.16M |
| September 30, 2016 | 47.80M |
| June 30, 2016 | 39.09M |
| March 31, 2016 | 31.25M |
| December 31, 2015 | 29.46M |
| September 30, 2015 | 50.78M |
| June 30, 2015 | 27.83M |
| March 31, 2015 | 27.18M |
| December 31, 2014 | 24.56M |
| September 30, 2014 | 22.42M |
| June 30, 2014 | 20.09M |
| March 31, 2014 | 18.11M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Avadel Pharmaceuticals Plc | 27.01M |
| Perrigo Co. Plc | 23.70M |
| GH Research Plc | 12.40M |
| Cosmo NV | -- |
| Axsome Therapeutics, Inc. | 46.08M |